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dertaken to better understand the factors influencing the funding decisions.
RESULTS: During this period three submissions were considered under the RoR
criteria, two in 2008 and one in 2009. None of these were approved for listing on the
basis of the RoR, however two were accepted on the basis of high clinical need and
high but acceptable cost-effectiveness ratio. No submission has requested consid-
eration under the RoR, or been assessed under this criteria by the PBAC, since
November 2009. In comparison, from 2008-2011, 4 new applications and 5 re-sub-
missions requested listing on the LSDP and 3 of these were successful.
CONCLUSIONS: Despite stricter criteria for the LSDP than the RoR, applications to
the LSDP have had a better success rate. The RoR has not been used to justify a
listing on the PBS for at least four years, perhaps indicating that these criteria are
no longer favoured by the PBAC.
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OBJECTIVES: In Brazil, the concepts of minimization cost are being applied in price
analyses of newpharmaceuticals since 2004,whenwas published the Resolution of
Brazilian Chamber of Economic Regulation of Pharmaceuticals (CMED) n° 2/2004.
The drugs are divided in two types: new drugs presentations and new molecules,
these are classified by two categories: I - New product with patent of molecule,
which has scientific evidences of benefits over the medications used on the same
treatment; II - New products which were not classified as category I. The prices
analyses of new drugs are classified by twomethods the lowest international price
and cost of treatment considering an existing medication traded in Brazil. The
category I take in the consideration the lowest international price and the category
II considering the cost of treatment and international price, the lowest of them. The
goal of this research is to evaluate the price regulation of new molecules over the
last eight years and all the consequences in terms of prices and a decrease of costs
for the society. METHODS: Only data of prices analyses assessed by Office of Eco-
nomic Assessment of New Technologies of Brazilian Health Surveillance Agency
(Anvisa), which supports the decisions of CMED, were evaluated. RESULTS: Ac-
cording to our statistics, 209 new molecules - category I and II - (over 563 presen-
tations) were analyzed. During the last eight years, the difference between the
price proposed by the laboratories and the price analyzed by Anvisa has been
reduced, as demonstrated bellow: Category I 21%; Category II 39%. CONCLUSIONS:
It suggests the prices are more in conformity of the resolution. In fact, the Resolu-
tion CMED n° 2/2004 brought rational price decrease and, in consequence, cost
decrease for the private and public sector, improving the efficiency of health care.
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OBJECTIVES: Shortages of antibiotics adversely impact health outcomes and
health care costs. We assessed the prevalence of shortages of systemic antibiotics
and evaluated the characteristics of the antibiotics in short supply as reported by
federal agencies and private health care providers in the US on June 1, 2011.
METHODS: Data were collected from the FDA, American Society of Health-System
Pharmacists (ASHP), and Brigham and Women’s Hospital (BWH) websites. The
units of analysis were active ingredient(s) and route of administration. The preva-
lence of shortageswas estimated as a percentage of the total number of products in
theUSmarket as of June 1, 2011.RESULTS:A total of 18 antibiotic active ingredients
with 20 routes of administration were in short supply as of June 1st, 2011. The
prevalence of shortages of systemic antibiotics varied from20.6% reported byASHP
to 3.1% reported by the FDA and BWH. Injectable antibiotics had the highest (28.3%)
rate of shortage followed by oral products (11.4%). Three shortageswere resolved as
of December 31, 2011. The average duration of shortage as of Dec-31-2011 was
589.2304.6 days. The average number of companies marketing the products in
short supply was 5.43.1, with 5 products having only 1 manufacturer. Generic
products were available for 95.0% of the drugs. The brand name product was dis-
continued for 55.0% of the drugs. The drugs in shortage had an average of 2.31.0
shortages from 2001 to 2011. Shortages resulting from discontinuation occurred
because of problems with manufacturing (35.0%), raw materials (15.0%), FDA reg-
ulatory issues (5.0%), and for unknown reasons (45.0%). CONCLUSIONS: Over one-
fourth of the injectable systemic antibiotics available in the United States were
reported in short supply. Problems with manufacturing and raw materials repre-
sented most of the reported causes of shortages. Additional research is needed to
assess the risk factors and causes of pharmaceutical shortages in theUnited States.
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OBJECTIVES: To estimate the impact of Medicare Part D on prescription and med-
ical utilization among Arizona’s senior dual eligible population. METHODS: This
study was a retrospective analysis of changes in pharmaceutical utilization and
physician visits among Arizona senior dual eligible (Medicaid and Medicare) ben-
eficiaries between the ages of 66 and 80 as of January 1, 2006 relative to a compar-
ison group (Medicaid beneficiaries between the ages of 50 and 62 as of January 1,
2006). Medical and pharmacy claims from the Medicaid program from January 1,
2005 to December 31, 2007 were used in this analysis. Differences between groups
with respect to over-the-counter (OTC) medications, benzodiazepines, total pre-
scription utilization, generic medication utilization, and physician visits were es-
timated using generalized estimating equations. RESULTS: The dual eligibles and
comparison group were similar in their level and trend of utilization of over-the-
counter (OTC) medications and benzodiazepines in the pre-Part D period. Follow-
ing implementation of Part D, therewas an immediate decline in utilization of both
OTCmedications and benzodiazepines in the dual eligibles relative to the compar-
ison group (p 0.001). An upward trend was observed for both groups during the
pre-Part D period for total prescription utilization and generic medication utiliza-
tion. After the implementation of Medicare Part D, utilization of these drug classes
was significantly lower among the dual eligibles relative to the comparison group
(p0.001). Trends in physician office visits were similar for the entire study period.
During the first month of Part D, however, the dual eligibles had a significantly
larger increase in physician visits over the previous month relative to the compar-
ison group (p0.001). CONCLUSIONS: This study suggests that medication use for
dual eligible Medicare beneficiaries was disrupted by the transition of outpatient
drug benefits from Medicaid to Medicare Part D.
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OBJECTIVES: Between $69 billion and $230 billion is spent on health care fraud
annually. Most health care fraud cases are initiated by private citizens (qui tam
relators), who receive up to 30% of recoveries. We reviewed recently concluded
Federal health care fraud activities and compared our findings to those reported
previously Kesselheim. METHODS: Data were from Taxpayers against Fraud and
Department of Justice websites (January 2006 to October 2010). Cases pursued un-
der the Federal False Claims Act (FCA), the most commonly employed law invoked
in these investigations, were identified. Information on allegations, recoveries, and
qui tam relator awards was abstracted. RESULTS: From 2006 to 2010, 116 Federal
health care FCA cases were identified, mainly involving improper billing (64%),
improper financial relationships (34%), and illegalmarketing (18%) concluded.Most
cases involved pharmaceuticalmanufacturers (27%), hospitals (20%), or health sys-
tems (15%). In comparison to cases without qui tam relators (39 cases, $1.9 billion in
recoveries), those with qui tam relators (77 cases, $12.4 billion in recoveries) had
greatermean per-case recoveries ($380million versus $110million for pharmaceu-
tical cases; $42 million versus $25 million for hospital cases; and $170 million
versus $34 million for health systems cases). Qui tam relators received $1.1 billion.
Among qui tam relator cases closed since 2006 versus 1996-2005, cases involving
hospitals and health systems decreased 84% and 30%, respectively (per-case recov-
eries increased 14-fold and 2.7-fold, respectively); and pharmaceutical manufac-
turers’ cases tripled (to 34) (per-case recoveries doubled to $380 million).
CONCLUSIONS: Since 2006, 116 health care FCA cases were settled, accounting for
$14.3 billion in recoveries. Qui tam relators continue to play a dominant role, ac-
counting for the majority of 70% of the cases and financial recoveries. New inves-
tigation approaches including field audits, task force investigations, and predictive
modeling investigations augment qui tam relator led investigations.
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OBJECTIVES: High prices of orphan medicines are a cause for concern as they put
pressure on pharmaceutical budgets and may negatively influence patient access
to pharmacotherapy. While repurposing of drugs is an attractive strategy to over-
come the logistical and financial burden of the first phases of medicine develop-
ment, we argue that repurposed medicines for rare indications, for which effec-
tiveness evidence has already been published, do not warrant high prices.
METHODS:We identified 16 examples of repurposedmedicines for rare indications
for which effectiveness evidence was published prior to the application for orphan
designation and compared Belgian hospital prices between the common disease
and the rare indication of the same medicine. RESULTS: In the majority of cases
(n 13), the pharmaceutical form of the medicine was identical for the common
and for the rare indication. Medicine prices (per defined daily dose) for the rare
indication were nearly the same as for the common disease for cladribine and
tadalafil, and ranged from a two-fold difference (e.g. aztreonam, sildenafil) to a
200-fold difference for histamine. Three medicines had a different pharmaceu-
tical form for the rare indication: medicines for the rare indication were at least
56 times more expensive than for the common disease. Hospital prices per dose
for the rare indication were at least 23 times higher than for the common
disease. CONCLUSIONS: This study suggests that the majority of these selected
repurposed medicines for rare indications are over-priced. This pricing practice is
not justified and adds to the budget impact of treating rare diseases. There is a need
to individually assess repurposed medicines taking into account the costs of re-
search and development and the costs of market access that can be attributed to
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the medicine for the rare indication as distinct from the costs of the medicine for
the common disease.
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OBJECTIVES: The present study contributes to and augments the few economic
attempts to explain medical non-compliance. To this end, an “economic invest-
ment model” is suggested as conceptual framework reflecting the three phases
typically observed in medical treatments: “invasion”, “high compliance” and ex-
pected variations in compliance behavior. Based on this framework a cost-neutral
incentive scheme is developed; the impact of this incentive scheme on adherence
is evaluated.METHODS: Behavioral predictionswere empirically evaluated by sug-
gesting an experimental design that incorporates the key features of the concep-
tual framework. Computerized economic experiments with investment decisions
over 12 periodswere run (September - December 2011)with subjects recruited from
a pool of approx. 1800 students from different fields of study. 107 and 102 subjects
participated in the baseline and in the incentive treatment, respectively. Instruc-
tionswere context-free, thus no associationswithmedical treatments, pharmacies
etc. could emerge, possibly influencing subjects’ decisions in an uncontrolled way.
RESULTS: In the baseline treatment, adherence drops significantly closely before
(p0.03, McNemar, two-sided) and closely after (p0.016, McNemar, two-sided) a
reference point (period 6), which is constituted by costs imposed by the invasion
phase. In the incentive treatment only one significant drop from period 9 to 10
(p.016, McNemar, two-sided) exists. Especially in the last periods of the experi-
ment the proportion of subjects switching to non-adhere is weakly significantly
higher in the baseline treatment than in the treatment with monetary incentives
(p0.06, Wilcoxon, two-sided). CONCLUSIONS: Decisions predicted by behavioral
economic theories similar to those documented in other contexts are at play in this
experimental setup and explain why adherence switches to non-adherence at
some point. By using financial incentives this switching point is shifted towards
the end of the “therapeutic treatment”. Thus, adherence is observed over a longer
span compared to a design providing no financial incentives.
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OBJECTIVES: Large amounts of health care cost are spent on drugs in Korea, 29.6%
of total health care expenditure in 2009, and these amounts are continuously in-
creasing. To control spending on prescription drugs we had tried to adopt the
reference pricing system in 2001, but it failed due to patients’ negative perception
and shortage of infrastructure. Recently, it is estimated that the technical circum-
stances are prepared. Yet the public perception has not been checked whether it
has been changed or not. The aim of this study was to ascertain the patients’
willingness to exchange the prescribed drug for the cheaper one in order to predict
the acceptability of the reference price system.METHODS: Nation-wide telephone
interview survey was conducted for 1000 consumers from October 19 to 26, 2011.
RESULTS: Patients were asked whether they would exchange the drug prescribed
by their doctor for the cheaper drug of which therapeutic effectiveness is equiva-
lent. Of 1000 respondents, 647(64.7%) answered “Yes (I will exchange)”. And the
reasons of the 353 consumers who responded “No (I will not exchange)” are; their
trust in doctor’s judgment (56.1%, n198), little confidence in the equivalence be-
tween the medications (35.1%, n124), and there is no great difference among the
cost ofmedicines in general (8.8%, n31).CONCLUSIONS: Patients’ attitude toward
lower price drug has been changed for last 10 years in Korea. They would likely to
choose cheaper drugs if information of exchangeable drug options and prices is
given at the time of prescribing or dispensing. It means that reference price system
would be acceptable by patients and contribute to reduce the pharmaceutical ex-
penditure in Korea. In addition, providing physicians with incentives to encourage
prescribing low pricemedicines and restoring consumer confidence in equivalence
of therapeutic effect are required to improve the effectiveness of the system.
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OBJECTIVES: Potential savings from generic drugs has become a key issue among
Canadian policy makers, with public drug programs in many Canadian provinces
reducing the amount they are willing to pay for generic drugs. This analysis exam-
ines generic drug spending in Canada, and looks at future patent expiries to esti-
mate the potential for savings in coming years. METHODS: This study examined
wholesale purchase data from IMS Brogan’s Canadian Drug Store and Hospital
Purchases Audit for all Canadian provinces between October 2004 and September
2010. Health Canada’s Patent Register and Drug Product Database were used to
estimate future dates of generic entry. RESULTS: Between 2004-05 and 2009-10,
purchases of generic drugs grew at 15.0% per year, three times faster than pur-
chases of brand name drugs. This increased the generic share of the Canadian drug
market from 17.0% to 25.9%. Further increases in the generic share are expected as
drugs with patents expiring between 2010 and 2014 accounted for 38.2% of all
purchases of prescription drugs in Canada in 2009. Drugs with patents expiring
beyond 2014 accounted for only 8.2% of drug purchases. CONCLUSIONS: Findings
suggest that there is potential for significant savings arising from new generic
competition in the next few years. The magnitude of these savings will depend on
the degree to which policy changes impact generic prices. However, theremay less
opportunity in the longer term. This issue is compounded by uncertainty as to the
regulatory requirements, manufacturing processes and pricing for “generic” ver-
sions of biologics.
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OBJECTIVES: To report ustekinumab dosing patterns in a large United States (U.S.)
retrospective healthcare claims database. METHODS: Patients with ustekinumab
prescriptions between 9/25/2009 and 12/31/2010 (first claim set index date) and
continuous activity in the Source® LX database (6 months pre- and 6 months
post-index) were included. Patients with evidence of other biologics during usteki-
numab treatment were excluded. Dosing was evaluated for the first 5 prescription
fills. Dose changeswere assessed for subsequent doses post-index and classified as
“higher than”, “same as”, or “lower than” the initial dose. The dosing interval was
defined as days between consecutive fills. Biologic experience was defined as  1
claim for another biologic pre-index. RESULTS: A total of 473 patients were evalu-
ated (meanSD agewas 4912 years; 46.3% female). 64.7% (n306) of patientswere
bio-experienced, while 35.3% (n167) had no history of biologic use before usteki-
numab (bio-naïve). Initial doses of 45 mg were observed for 69.3% of bio-experi-
enced and 72.5% of bio-naïve patients. Initial doses of 90 mg were observed for
30.7% of bio-experienced and 27.5% of bio-naïve patients. Subsequent doses were
the same as or lower than the initial dose for the majority of all (92.2%-96.8%),
bio-experienced (91.6%-97.7%), and bio-naïve (90.2%-95.2%) patients at each fill.
Overall median/mean dosing interval was 28/34 days for the first to second fill.
Median/mean dosing intervals for subsequent fills spanned 86-88/85-89 days. Dos-
ing intervals were similar among bio-experienced and bio-naïve patients.
CONCLUSIONS: In this longitudinal study of ustekinumab utilization in a US
healthcare claims database, nearly three-quarters of ustekinumab users had prior
treatmentwith biologics. Over two-thirds of initial ustekinumab doseswere 45mg.
Most patients remained at or below their starting dose. Dosing intervals were con-
sistent with prescribing recommendations (approximately one month for first 2
doses, followed by quarterly intervals). Dosing patterns in bio-experienced and
bio-naïve patients were similar.
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OBJECTIVES: To identify factors associated with primary nonadherence [PNA].
METHODS: This retrospective cohort study identified all new prescriptionswritten in
an integrated health care system for 10 therapeutic drug groups over a three-month
period (12/1/2009 - 2/28/2010). Study drugs included: antiinfectives, analgesics, mi-
graine medications, antidiabetics, osteoporosis medications, cardiovascular agents,
antihyperlipidemics, antiasthmatics, antidepressants, and anticoagulants. PNA was
defined as the failure to fill a prescription within 14 days of when it was written.
Stepwise multivariable logistic regression was used to identify significant patient,
provider and prescription characteristics associated with PNA. RESULTS: A total of
569,095 new prescriptions were written for the study drugs of interest during the
study period. Across all drug groups, the PNA rate was 9.8%. PNA rates for individ-
ual drug groups varied and were highest for osteoporosis medications (22.4%) and
antihyperlipidemics (22.3%). Patients were more likely to be primary nonadherent
if they were black, were not prescribed any drug from the same therapeutic drug
group during the past year, or had certain baseline comorbidities. Also, patients
who received brand name or multiple concomitant prescriptions were more likely
to be primary nonadherent. In contrast, patientswhofilled at least one prescription
in the prior year, had dual insurance orMedicaid coverage, or had a prescription for
a symptomatic disease were more likely to fill their prescription. Patients who
received prescriptions written by emergency medicine, pediatrics, or urgent care
were less likely to be primary nonadherent. Factors associated with PNA were
mostly consistent across all drug groups, but the estimated direction and signifi-
cance of some factors, such as patient gender and age, depended on whether the
treatment was acute or chronic. CONCLUSIONS: These results may be used to
facilitate clinicians and payers in making informed decisions when designing and
implementing cost-effective patient interventions to improve overall adherence to
medications.
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OBJECTIVES: To compare rates of Complementary and AlternativeMedicine (CAM)
use among individuals with and without disabilities.METHODS:We used a cross-
sectional design. Our data source was the 2007 National Health Interview Survey
files and the Adult Complementary and AlternativeMedicine Supplement. Individ-
A16 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 – A 2 5 6
